Publication Name	World Journal of Gastroenterology
Manuscript ID	30371
Country	Canada

Received	2016-09-30 10:31
Peer-Review Started	2016-09-30 17:45
First Decision by Editorial Office Director
Return for Revision	2016-12-02 10:50
Revised	2016-12-09 05:23
Publication Fee Transferred
Second Decision by Editor	2016-12-16 17:20
Second Decision by Editor-in-Chief	2016-12-19 15:09
Final Decision by Editorial Office Director	2016-12-21 16:20
Articles in Press	2016-12-21 16:20
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-12-25 15:41
Publish the Manuscript Online	2017-01-05 11:10

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Randomized Controlled Trial
Article Title	Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
Manuscript Source	Invited Manuscript
All Author List	Tisha R Joy, Charles A McKenzie, Rommel G Tirona, Kelly Summers, Shannon Seney, Subrata Chakrabarti, Neel Malhotra and Melanie D Beaton
Funding Agency and Grant Number	Funding Agency Grant Number Physicians' Services Incorporate Foundation 10q2083 Academic Medical Organization of Southwestern Ontario F10-002 Program of Experimental Medicine and Department of Medicine Academic (partly) Funds from Western University, London, Ontario, Canada (partly)
Corresponding Author	Dr. Melanie D Beaton, Associate Professor, Department of Medicine, Division of Gastroenterology, London Health Sciences Centre, Western University, 339 Windermere Road, London, Ontario N6A 5A5, Canada. melanie.beaton@lhsc.on.ca
Key Words	Sitagliptin; Randomized controlled trial; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Fibrosis; Magnetic resonance imaging; Hepatic steatosis; Insulin resistance; Platelet aggregation
Core Tip	Presently, there is no approved medical therapy for non-alcoholic steatohepatitis (NASH). In this randomized placebo-controlled trial, the effect of sitagliptin on liver fibrosis in patients with NASH after 24 wk was evaluated. There was no significant improvement with the use of sitagliptin on liver fibrosis, total non-alcoholic fatty liver disease activity score or its individual components. Similarly, there were no significant improvements in liver enzymes, adipocytokines, lipid profile, thrombosis parameters, or adipose distribution. There was a strong correlation between hepatic fat % measured using the MRI IDEAL technique and hepatic steatosis on liver biopsy.
Publish Date	2017-01-05 11:10
Citation	Joy TR, McKenzie CA, Tirona RG, Summers K, Seney S, Chakrabarti S, Malhotra N, Beaton MD. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol 2017; 23(1): 141-150
URL	http://www.wjgnet.com/1007-9327/full/v23/i1/141.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i1.141

Full Article (PDF)	WJG-23-141.pdf
Full Article (Word)	WJG-23-141.doc